Specific coagulation impairment in patients with and without extracorporeal lung support during COVID-19-ARDS

Specific coagulation impairment in patients with and without extracorporeal lung support during COVID-19-ARDS - -

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025519

Enrollment

Registered

2021-06-08

Start date

2021-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J80.03 D68.01

Interventions

Group 1: In patients with ECMO procedures for COVID-ARDS, advanced blood coagulation parameters are determined during the course of the disease and therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: severe COVID-19-ARDS

Exclusion criteria

Exclusion criteria: ECMO-therapy not indicated

Design outcomes

Primary

Measure	Time frame
Frequency and severity of acquired coagulation disorders such as acquired von Willebrand syndrome.	—

Secondary

Measure	Time frame
Incidence of further coagulation disorders, mortality	—

Countries

Germany

Contacts

Public ContactJohannes Kalbhenn

Klinik für Anästhesie und Intensivmedizin Universitätsklinikum Freiburg

johannes.kalbhenn@uniklinik-freiburg.de076127023100

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026